United States of America

FDA Approves Leucovorin for Rare Genetic Brain Disorder

Is the FDA's approval of leucovorin a milestone for patients or a debacle following unproven autism claims?

Published 2 days ago

FDA Approves Leucovorin for Rare Genetic Brain Disorder

story

Above: The FDA's White Oak campus in Silver Spring, Maryland, on July 17, 2025. Image credit: ISSAM AHMED/AFP /Getty Images

The Spin

Pro-establishment narrative

The FDA's approval of leucovorin for cerebral folate deficiency marks a significant milestone for patients with this rare genetic condition who previously had no treatment options to turn to. The groundbreaking decision is yet another example of the FDA's commitment to addressing the critical needs of individuals who are suffering from severe neurological complications.

U.S. Food and Drug Administration

Establishment-critical narrative

The administration's handling of leucovorin has been a total debacle. After hyping it as a potential autism treatment on live television, the administration has quietly walked back its claims after admitting it lacks the evidence to support its observations. In the future, perhaps the White House should make announcements after obtaining the proof rather than before.

Jonathan Reiner on X

Jeffrey S. Morris on X